INSIGHTS ON CLINICAL TRIAL PARTNERING

• 6 Steps To Help You Choose The Right Clinical Trial Partner

  The right digital partner can unlock speed, scale, and collaboration that can transform the future of your pipeline. Learn the six steps to help you choose the right partner for your trials.

• Strong Bookings And The Disruption Gap Nobody Is Talking About

  Understand the real impact of AI on CRO valuations and clinical trial stability. Explore why market data contradicts the "disruption" narrative and what it means for the future of the industry.

• Accelerating A Complex Global Cardiovascular Outcomes Trial Via Coordinated Execution

  Coordinating CRO, clinical supply, and central lab activities from the start shaped how a 1,500-site, 35-country cardiovascular outcomes trial moved ahead of plan on activation and enrollment.

• Harnessing AI for Pre-Award Landscape Analysis And Site Selection

  AI-driven insights transform site selection and feasibility, enabling faster decisions and reducing risk. Predictive modeling and real-time data improve pre-award planning and trial outcomes.

• We Help Sites Coordinate Payments, Travel, And Participant Support

  10/8/2026

  Splitting payments, travel, and participant services can add work for sites. See how a connected model eases coordination and gives participants clearer support.

• Start Fast, Scale Seamlessly: Why A Different Oncology Model Was Needed

  5/1/2026

  Oncology programs don’t lose momentum because the science fails, but because execution fractures as complexity grows. Learn how continuity-first operating models help sponsors move faster.

• What Sponsors Need To Know Before They Get To The IRB & IBC

  5/13/2026

  Gene therapy requires early, rigorous safety planning and command of pediatric and biosafety rules. Early committee engagement reduces delays and strengthens high‑stakes trials.

• Site Initiation Visits For Clinical Trials: Ocular Endpoint Planning For Sponsors And CROs

  2/5/2026

  Learn how expert site initiation visit (SIV) planning masters complex endpoints like OCT and BCVA, eliminates data variability, and prevents the costly need for trial rescue.

• New Purpose-Built Facility For Large-Scale Sterile Fill/Finish Operations

  7/17/2025

  Expanding capacity for late-phase clinical and large-scale commercial small molecule and biologic drugs, a new facility boosts sterile fill/finish capabilities.